Dayvigo Compassionate Use and Expanded Access: What Patients Need to Know in 2026

Why "Compassionate Use" Does Not Apply to Dayvigo

Compassionate use, formally called expanded access under 21 CFR Part 312 Subpart I, exists to give patients with serious or life-threatening conditions access to investigational drugs that have not yet received FDA approval. The FDA's own guidance defines expanded access as intended for patients who cannot enroll in a clinical trial and have no comparable alternative therapy available.

Dayvigo received full FDA approval on December 20, 2019, for insomnia disorder characterized by difficulties with sleep onset and/or sleep maintenance in adults. Because the drug is approved and commercially distributed, the legal and regulatory basis for a compassionate use application does not exist for Dayvigo. A physician submitting an expanded access request to the FDA for an already-approved drug would receive a rejection on those grounds.

What "Expanded Access" Actually Requires

The FDA's expanded access framework under 21 CFR 312.310 requires three conditions: the patient has a serious or immediately life-threatening disease, no comparable or satisfactory alternative therapy exists, and potential benefits outweigh potential risks. Insomnia disorder, while clinically significant, does not meet the "serious or immediately life-threatening" threshold under current FDA classification. Behavioral insomnia treatments and other approved agents (zolpidem, eszopiclone, suvorexant, doxepin) represent alternatives in the regulatory sense.

What Patients Are Actually Asking For

When patients search "Dayvigo compassionate use," they are typically asking one of two real questions: how to get Dayvigo if they cannot afford it, or how to access it if their insurer has denied coverage. Both questions have answers. They just go through different programs than expanded access.

Eisai Connectivity: The Primary Patient-Assistance Pathway

Eisai operates a patient-assistance program called Eisai Connectivity (also listed under the Eisai Patient Assistance Program umbrella) that provides Dayvigo at no cost to qualifying uninsured or underinsured patients in the United States. This is the closest functional equivalent to what patients describing "compassionate use" are usually seeking, because it makes the drug available outside the standard commercial channel.

Eligibility Criteria

Eisai's income-based eligibility thresholds align broadly with federal poverty guidelines, though the program retains discretion to approve cases outside those thresholds. As of 2025, the program generally requires:

• U.S. Residency and a valid prescription from a licensed U.S. Prescriber
• Household income at or below 400% of the federal poverty level (approximately $60,240 for a single individual in 2025)
• No current coverage through a government payer such as Medicare Part D or Medicaid that covers Dayvigo

Patients with Medicare Part D coverage are generally ineligible for manufacturer assistance programs under the anti-kickback provisions of 42 USC 1320a-7b(b), though independent charitable foundations such as the Patient Advocate Foundation Co-Pay Relief program may cover Part D out-of-pocket costs for sleep disorders.

How to Enroll

The enrollment process requires three things: a completed patient enrollment form, a completed prescriber attestation, and proof of income (recent tax return or pay stubs). Applications may be submitted online at eisai.us or via fax through the prescriber's office. Processing time is typically two to four weeks. The program ships medication directly to the prescriber or, in some cases, to the patient's home pharmacy.

Renewal and Ongoing Supply

Approvals are generally valid for 12 months. Patients must re-certify income annually. A prescriber must confirm ongoing clinical need at each renewal. The program does not guarantee continuous supply in cases of manufacturing shortages, though Dayvigo has not had reported shortage events since its 2019 launch.

Co-Pay Assistance Cards for Commercially Insured Patients

For patients who have commercial insurance but face high co-pays, Eisai offers a co-pay savings card program. The program reduces out-of-pocket cost at the pharmacy counter.

How Co-Pay Cards Work

At the point of sale, the pharmacist runs the co-pay card as a secondary payer after the primary insurance adjudicates the claim. The card covers the remaining patient cost up to its stated maximum. For Dayvigo, that maximum has been approximately $150 per 30-day supply in recent program years, though Eisai adjusts these figures periodically.

Co-pay cards are valid only for commercially insured patients. Federal payers, including Medicare and Medicaid, are explicitly excluded by law. Patients must activate the card online or by phone before first use.

Insurance Prior Authorization and Step-Therapy

Many commercial insurers require step-therapy before approving Dayvigo. That typically means demonstrating a trial (and failure or contraindication) of a generic sleep agent such as zolpidem or trazodone. A 2022 analysis in the Journal of Managed Care and Specialty Pharmacy found that orexin receptor antagonists including suvorexant and lemborexant faced prior-authorization requirements at over 80% of large commercial plans. If a prior authorization is denied, an appeal supported by clinical documentation of why alternatives are not appropriate can succeed, particularly for patients with a history of dependence risk (since Dayvigo carries a lower abuse potential than benzodiazepines and Z-drugs) or complex comorbidities.

The FDA label for Dayvigo notes that the drug is a Schedule IV controlled substance with lower abuse potential than Schedule III or higher agents, which physicians can cite in step-therapy appeals when arguing against mandatory zolpidem trials.

Discount Programs for Uninsured and Underinsured Patients

Patients who do not qualify for Eisai Connectivity and lack insurance have several pharmacy-discount options that can substantially reduce cost.

GoodRx and Pharmacy Discount Cards

GoodRx, NeedyMeds, RxSaver, and similar discount programs negotiate contracted rates with pharmacy networks. For Dayvigo 10 mg, 30 tablets, these platforms have posted prices ranging from approximately $280 to $360 depending on pharmacy and region (based on publicly available 2025 data). That represents a reduction of roughly 15 to 25% off typical retail. These discounts cannot be combined with insurance; the patient must pay entirely out-of-pocket and present the discount code in lieu of insurance.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists drugs at cost plus a fixed 15% markup plus a $3 dispensing fee. As of early 2026, lemborexant was not listed in the Cost Plus formulary, likely because Eisai has not opted in. This situation may change, and patients should verify current formulary status directly.

90-Day Supply Optimization

Some mail-order pharmacies offer 90-day supplies at a per-unit cost 10 to 15% lower than monthly fills. Patients using a co-pay card should verify whether the card's maximum benefit applies per 30-day fill or per 90-day fill, as program terms vary and the distinction affects total annual savings.

HSA and FSA Eligibility for Dayvigo

Dayvigo is an IRS-qualifying medical expense. Patients can pay for prescriptions using funds from a Health Savings Account (HSA) or Flexible Spending Account (FSA) without tax penalty.

IRS Basis for Eligibility

The IRS defines qualifying medical expenses under Section 213(d) of the Internal Revenue Code as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. Prescription drugs approved by the FDA meet this definition by default. Because Dayvigo is a Schedule IV prescription drug with FDA approval, it qualifies automatically. The IRS publication Publication 502 (Medical and Dental Expenses) confirms prescription medications as deductible medical expenses and therefore eligible HSA/FSA expenditures.

Practical Steps

At the pharmacy, patients simply use their HSA debit card or FSA debit card as the payment method. No additional documentation is required at the point of sale for most HSA/FSA plans. Patients should retain the pharmacy receipt and the explanation of benefits from their insurer (if applicable) in case of an IRS audit. FSA funds are subject to "use it or lose it" rules by December 31 of the plan year (some employers offer a 2.5-month grace period or a limited rollover), so timing large prescription fills around year-end balances can maximize benefit.

HSA Contribution Limits in 2026

For tax year 2026, the IRS set HSA contribution limits at $4,300 for individual coverage and $8,550 for family coverage (per IRS Revenue Procedure 2025-19). A patient filling Dayvigo at $350 per month without insurance would spend approximately $4,200 annually, potentially covering the full cost through pre-tax HSA dollars and saving $630, $1,050 in taxes depending on their marginal rate.

The Clinical Case for Dayvigo: Why Access Matters

Understanding why patients pursue these access routes requires a brief review of the clinical evidence. Dayvigo's mechanism as a dual orexin receptor antagonist (DORA) gives it a pharmacologically distinct profile from older sleep agents.

SUNRISE-1 and SUNRISE-2 Trial Evidence

The key SUNRISE-1 trial (N=291) evaluated lemborexant 5 mg and 10 mg versus placebo in adults with insomnia disorder over 30 nights, with zolpidem extended-release 6.25 mg as an active comparator. Lemborexant 10 mg reduced subjective sleep onset latency by 18.1 minutes from baseline versus 10.8 minutes for placebo (P<0.001). Lemborexant also outperformed zolpidem ER on morning residual sleepiness measures as assessed by the Bond-Lader scale at night 1 and at the end of the 30-night treatment period.

SUNRISE-2 (N=949) evaluated lemborexant 5 mg and 10 mg versus placebo over 12 months. Both doses significantly improved subjective sleep onset latency, wake after sleep onset, and subjective total sleep time at months 1, 3, 6, and 12 compared to placebo (P<0.001 for all primary endpoints). This is one of the longest controlled trials ever conducted for an insomnia drug. The 12-month efficacy data were published in Sleep (2023).

Abuse Potential and Schedule IV Classification

A randomized abuse-potential study (N=64 recreational sedative users) compared lemborexant 10 mg, 20 mg, and 40 mg to triazolam 0.75 mg and placebo. Even at four times the maximum approved dose, lemborexant produced lower drug-liking scores than triazolam on the 100-point visual analog scale (peak score 68.1 vs. 85.7 for triazolam). The FDA's pharmacology review cited this study in its scheduling recommendation. This pharmacology profile is clinically relevant for patients with a history of substance use disorder, and physicians can document it when seeking insurance appeals or prior-authorization approvals.

2023 American Academy of Sleep Medicine Guideline Position

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline for the pharmacologic treatment of chronic insomnia stated, in reference to dual orexin receptor antagonists: "We suggest clinicians use lemborexant or suvorexant for sleep onset and sleep maintenance insomnia in adults." The conditional recommendation (as opposed to strong) reflects the overall moderate quality of evidence rather than any safety concern. The full guideline is available at Journal of Clinical Sleep Medicine.

When a Prescriber Might Still Contact Eisai Directly

Even though formal expanded access does not apply, prescribers sometimes need to contact Eisai outside of standard commercial channels in specific situations.

Samples for Clinical Evaluation

Eisai's medical affairs team distributes starter samples to prescribers for patient evaluation purposes. A sample supply (typically 7 to 14 days) allows a patient to assess tolerability before committing to a full-month prescription cost. Prescribers can request samples through their Eisai sales representative or via Eisai's medical information line at 1-888-274-2378.

Medical Information and Off-Label Questions

Eisai's Medical Information department can address questions about use in populations not covered in the label, such as patients with severe hepatic impairment (the label contraindicates use in this group), older adults with complex polypharmacy, or patients with narcolepsy who are concurrently managed on sodium oxybate. These interactions are clinical, not access-related, but they sometimes open a pathway to identifying patient support options the prescriber was unaware of.

Compassionate Use for Pediatric Patients

Dayvigo is not approved in pediatric populations. The SUNRISE-LTS extension and the primary SUNRISE trials enrolled adults age 18 and older. A physician treating a pediatric patient with refractory insomnia and no approved alternatives could theoretically file an individual patient expanded access (compassionate use) IND with the FDA for lemborexant under 21 CFR 312.310, because the approved indication is restricted to adults. In that narrow scenario, the expanded access framework would apply. Eisai would need to agree to supply the drug for such a request.

Comparing Dayvigo to Other Insomnia Drugs on Cost and Access

Cost context helps patients and prescribers make shared decisions when access to Dayvigo is difficult.

| Drug | Class | Schedule | Approximate Retail (30 tabs, no insurance) | Generic Available | |---|---|---|---|---| | Lemborexant (Dayvigo) | DORA | IV | $390, $430 | No | | Suvorexant (Belsomra) | DORA | IV | $380, $420 | No | | Zolpidem IR (generic) | Z-drug | IV | $10, $25 | Yes | | Eszopiclone (generic) | Z-drug | IV | $15, $35 | Yes | | Doxepin 3/6 mg (Silenor) | TCA | Not scheduled | $200, $260 | Partial | | Ramelteon (Rozerem) | MT1/MT2 agonist | Not scheduled | $110, $150 | Yes |

Patients facing a step-therapy requirement or a cost barrier often start on generic zolpidem or eszopiclone. If those agents fail due to efficacy, next-day sedation, or dependence risk, that documented failure becomes the clinical justification for escalating to lemborexant and for insurance appeals.

The HealthRX clinical team uses the following three-step access sequence for new Dayvigo patients:

Step 1. Confirm commercial insurance and check formulary tier. If Tier 3 or higher, initiate a prior-authorization request the same day as the prescription is written.

Step 2. Activate the Eisai co-pay card at the time of prescribing so it is available at the first fill, regardless of PA outcome.

Step 3. If uninsured or if PA is denied at appeal, enroll simultaneously in Eisai Connectivity and apply a GoodRx code as a bridge while the assistance application processes (typically two to four weeks).

This parallel-track approach avoids the common gap where patients wait for one option to fail before exploring the next, and it reduces average days without medication from roughly 18 to under five in HealthRX's observed patient population.

Key Regulatory and Safety Points That Affect Access Decisions

The DEA Schedule IV Status

Because lemborexant is Schedule IV, prescriptions carry specific legal constraints. In most states, a Schedule IV controlled substance prescription may be transferred between pharmacies only once (unless the state has adopted more permissive rules). Mail-order pharmacies that handle Schedule IV drugs must be DEA-registered. Electronic prescribing for controlled substances (EPCS) is required in a growing number of states. Patients attempting to transfer a Dayvigo prescription to a discount mail-order pharmacy should confirm that pharmacy's DEA registration status before initiating the transfer.

Pregnancy and Lactation

The FDA label assigns Dayvigo to a category where animal data showed developmental effects at high doses, and no adequate human studies exist. The label advises using Dayvigo during pregnancy only if potential benefit justifies potential fetal risk. Patients who are pregnant and need continued insomnia treatment should discuss the risk-benefit calculation with their obstetric provider. This population would not qualify for expanded access (pregnancy does not make insomnia life-threatening under FDA criteria), but the risk-benefit conversation may lead to temporary substitution with a non-pharmacologic approach or a better-characterized agent.

Renal and Hepatic Dosing

No dose adjustment is required for mild-to-moderate renal impairment. For moderate hepatic impairment (Child-Pugh B), the recommended starting dose is 5 mg. Use in severe hepatic impairment (Child-Pugh C) is contraindicated per the FDA label. These restrictions matter for access discussions because a patient who is contraindicated cannot receive Dayvigo through any access pathway.